Beam Therapeutics Inc.

Informe acción NasdaqGS:BEAM

Capitalización de mercado: US$2.4b

Salud financiera de hoja de balance de Beam Therapeutics

Salud financiera controles de criterios 6/6

Beam Therapeutics tiene un patrimonio de los accionistas total de $791.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.2B y $380.1M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$925.76m
PatrimonioUS$791.32m
Total pasivoUS$380.05m
Activos totalesUS$1.17b

Actualizaciones recientes sobre salud financiera

Recent updates

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 07

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

Sep 29

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Slow Developmental Progress, But Promising Potential

Jul 01

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

Nov 01
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Apr 08
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Beam Therapeutics: Now Is Not The Right Time To Own

Sep 15

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Aug 09

Beam drops 19% as FDA issues clinical hold on blood cancer candidate

Aug 01

Revisiting Beam Therapeutics Among Collaborative Catalysts

Jul 10

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Apr 21

Beam Therapeutics: Getting More And More Interesting

Apr 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

Jan 19

Beam Therapeutics: An Early Company In A Promising Field

Dec 27

Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

Dec 20

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

Oct 01

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($945.5M) de BEAM superan a sus pasivos a corto plazo ($166.2M).

Pasivo a largo plazo: Los activos a corto plazo de BEAM ($945.5M) superan a sus pasivos a largo plazo ($213.8M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: BEAM está libre de deudas.

Reducción de la deuda: BEAM no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BEAM tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: BEAM dispone de suficiente cash runway para 2.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 19.4% cada año.


Descubre empresas con salud financiera